2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzole
2005
Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.
Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. The Journal Of Clinical Psychiatry 2005, 66: 1492-3. PMID: 16420092, DOI: 10.4088/jcp.v66n1121d.Peer-Reviewed Original ResearchConceptsGlutamate-modulating agentsBorderline personality disorderSelf-injurious behaviorBeneficial effectsPersonality disorderInitial evidence